Inclusion Criteria:

          -  Histologically or cytologically documented locally advanced or recurrent NSCLC not
             eligible for curative surgery and/or definitive radiotherapy with or without
             chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC

          -  No prior systemic treatment for metastatic NSCLC

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  High tumor tissue PD-L1 expression

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1
             (RECIST v1.1)

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Known mutation in the EGFR gene or an ALK fusion oncogene

          -  Symptomatic, untreated, or actively progressing central nervous system metastases

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis

          -  Malignancies other than NSCLC within 5 years, with the exception of those with a
             negligible risk of metastasis or death treated with expected curative outcome

          -  Severe infection within 4 weeks prior to initiation of study treatment

          -  Positive test result for human immunodeficiency virus (HIV)

          -  Active hepatitis B or hepatitis C

          -  Treatment with investigational therapy within 28 days prior to initiation of study
             treatment

          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
             anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies

          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination
             half-lives prior to initiation of study treatment